Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech believes strong safety profile and resistance to viral breakthrough could move setrobuvir past Pharmasset's PSI-7977 and other polymerase inhibitors in development in hepatitis C.